AR049560A2 - Formas cristalinas de (2s,3s,5s)-2-(2,6-dimetilfenoxiacetil) amin 3-hidroxi-5-(2-(1-tetrahidropirimid-2-onil)-3-metilbutanol)amin-1,6-difenilhexano (lopinavir) - Google Patents

Formas cristalinas de (2s,3s,5s)-2-(2,6-dimetilfenoxiacetil) amin 3-hidroxi-5-(2-(1-tetrahidropirimid-2-onil)-3-metilbutanol)amin-1,6-difenilhexano (lopinavir)

Info

Publication number
AR049560A2
AR049560A2 ARP050102702A ARP050102702A AR049560A2 AR 049560 A2 AR049560 A2 AR 049560A2 AR P050102702 A ARP050102702 A AR P050102702A AR P050102702 A ARP050102702 A AR P050102702A AR 049560 A2 AR049560 A2 AR 049560A2
Authority
AR
Argentina
Prior art keywords
amin
lopinavir
hydroxy
tetrahydropirimid
dimethylphenoxiacetile
Prior art date
Application number
ARP050102702A
Other languages
English (en)
Inventor
Daniel Dickman
Sanjay Chemburkar
James Fort
Rodger Henry
David Lechuga-Ballesteros
Yuping Niu
William Porter
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049560(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/793,536 external-priority patent/US6608198B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR049560A2 publication Critical patent/AR049560A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Formas cristalinas hidratadas, las formas cristalinas solvatadas y las formas cristalinas de (2S, 3S, 5S)-2-(2,6-dimetilfenoxiacetil) amin-3-hidroxi-5-(2-(1-tetrahidropirimid-2-onil)-3-metilbutanoil)amin-1,6-difenilhexano (lopinavir), asi como las formas substancialmente puras de todas las formas anteriormente mencionadas. El lopinavir es de utilidad en la inhibicion de la proteasa del VIH y la inhibicion de una infeccion por VIH.
ARP050102702A 2000-03-30 2005-06-29 Formas cristalinas de (2s,3s,5s)-2-(2,6-dimetilfenoxiacetil) amin 3-hidroxi-5-(2-(1-tetrahidropirimid-2-onil)-3-metilbutanol)amin-1,6-difenilhexano (lopinavir) AR049560A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53825700A 2000-03-30 2000-03-30
US09/793,536 US6608198B2 (en) 2000-03-30 2001-02-27 Crystalline pharmaceutical

Publications (1)

Publication Number Publication Date
AR049560A2 true AR049560A2 (es) 2006-08-16

Family

ID=27065762

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP010101522A AR033360A1 (es) 2000-03-30 2001-03-29 Formas cristalinas de (2s,3s,5s)-2-(2,6-dimetilfenoxiacetil)amin-3-hidroxi-5-(2-(1-tetrahidropirimid-2-onil)-3-metilbutanoil) amin-1,6-difenilhexano (lopinavir)
ARP050102702A AR049560A2 (es) 2000-03-30 2005-06-29 Formas cristalinas de (2s,3s,5s)-2-(2,6-dimetilfenoxiacetil) amin 3-hidroxi-5-(2-(1-tetrahidropirimid-2-onil)-3-metilbutanol)amin-1,6-difenilhexano (lopinavir)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP010101522A AR033360A1 (es) 2000-03-30 2001-03-29 Formas cristalinas de (2s,3s,5s)-2-(2,6-dimetilfenoxiacetil)amin-3-hidroxi-5-(2-(1-tetrahidropirimid-2-onil)-3-metilbutanoil) amin-1,6-difenilhexano (lopinavir)

Country Status (22)

Country Link
EP (1) EP1268442A2 (es)
JP (1) JP2003529592A (es)
KR (1) KR100773258B1 (es)
CN (2) CN1330639C (es)
AR (2) AR033360A1 (es)
AU (3) AU2001250920B2 (es)
BG (1) BG107165A (es)
BR (1) BR0109433A (es)
CA (1) CA2403635A1 (es)
CZ (1) CZ20023529A3 (es)
HU (1) HUP0302675A3 (es)
IL (1) IL151551A0 (es)
MX (1) MXPA02009559A (es)
MY (1) MY128296A (es)
NO (1) NO325005B1 (es)
NZ (1) NZ521183A (es)
PE (1) PE20011232A1 (es)
PL (1) PL359727A1 (es)
SA (2) SA06270303B1 (es)
SK (1) SK14832002A3 (es)
TW (1) TWI284640B (es)
WO (1) WO2001074787A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
EP2393786B1 (en) * 2009-02-06 2014-01-22 Hetero Research Foundation Novel polymorphs of lopinavir
CA2770338A1 (en) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis c virus
CN112830899A (zh) * 2021-01-18 2021-05-25 合肥华方医药科技有限公司 一种洛匹那韦新晶型及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound

Also Published As

Publication number Publication date
SA01220270B1 (ar) 2006-11-14
CA2403635A1 (en) 2001-10-11
NZ521183A (en) 2004-03-26
HUP0302675A2 (hu) 2003-12-29
NO325005B1 (no) 2008-01-14
AR033360A1 (es) 2003-12-17
MXPA02009559A (es) 2003-05-21
SA06270303B1 (ar) 2009-08-02
IL151551A0 (en) 2003-04-10
NO20024679D0 (no) 2002-09-30
WO2001074787A3 (en) 2002-02-07
CN101066952A (zh) 2007-11-07
AU5092001A (en) 2001-10-15
KR20030011807A (ko) 2003-02-11
SK14832002A3 (sk) 2003-02-04
NO20024679L (no) 2002-09-30
HUP0302675A3 (en) 2004-03-29
MY128296A (en) 2007-01-31
KR100773258B1 (ko) 2007-11-05
EP1268442A2 (en) 2003-01-02
CN1330639C (zh) 2007-08-08
AU2001250920B2 (en) 2006-06-29
WO2001074787A2 (en) 2001-10-11
JP2003529592A (ja) 2003-10-07
BG107165A (bg) 2003-07-31
AU2006222711A1 (en) 2006-10-19
PE20011232A1 (es) 2001-12-08
PL359727A1 (en) 2004-09-06
BR0109433A (pt) 2004-08-10
TWI284640B (en) 2007-08-01
CN1422259A (zh) 2003-06-04
CZ20023529A3 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
ATE367394T1 (de) Anreicherung in der zelle an phosphonat analoga von hiv protease inhibitor verbindungen und die verbindungen selbst
MA27643A1 (fr) Utilisation de n-alkyl-4-methyleneamino-3-hydroxy-2-pyridones en tant qu'agents antimicrobiens
CL2009001844A1 (es) Forma de dosificacion farmaceutica solida que comprende lopinavir y ritonavir formulados en forma de dispersion solida o solucion solida, un polimero soluble en agua y un tensioactivo con valores de hlb de entre 4 y 10, util en el tratamiento de una infeccion por vih (divisional sol. 393-06).
MY142948A (en) Benzophenones as inhibitors of reverse transcriptase
AR049560A2 (es) Formas cristalinas de (2s,3s,5s)-2-(2,6-dimetilfenoxiacetil) amin 3-hidroxi-5-(2-(1-tetrahidropirimid-2-onil)-3-metilbutanol)amin-1,6-difenilhexano (lopinavir)
SE0102315D0 (sv) Compounds
BR0012752A (pt) Benzofuril piperazinas e benzofuril homopiperazinas: agonistas de serotonina
UY26380A1 (es) Inhibidores de fab i
BR0215405A (pt) Composições e processos de uso de collajolie
CL2008003819A1 (es) Compuestos derivados del acido 2-cetoamino benzoico sustituido, inhibidores del virus de la hepatitis c; composicion farmaceutica; y su uso en el tratamiento de una infeccion por vhc.
CO5540347A2 (es) Derivados de dipeptido que contiene un grupo 2-tioacilo n-terminal como inhibidores de vasopeptidasa
NO20052788L (no) N-sulfonyl-4-metylenamino-3-hydroksy-2-pyridoner som antimikrobielle midler
IL156774A0 (en) Inhibitors of cruzipain and other cysteine proteases
MX2007009655A (es) Inhibidores de la proteasa del vih.
DE60221508D1 (de) Aminosäurederivate als hiv-protease-inhibitoren
EP1947094A3 (en) Process for the preparation of taxane derivatives
ATE499837T1 (de) Antimikrobielle zusammensetzungen, die ethanolamid-puffer und biguanid- desinfektionsmittel enthalten
PE74799A1 (es) Combinaciones antivirales
ATE348803T1 (de) Tryptase-inhibitoren
TH22511A (th) Use of quinoxalines in combination with protease inhibitors as medicaments for treation, aids and/or hiv infections

Legal Events

Date Code Title Description
FB Suspension of granting procedure